50 related articles for article (PubMed ID: 7591887)
21. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
22. Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment.
Hanks GE; Hanlon AL; Hudes G; Lee WR; Suasin W; Schultheiss TE
J Clin Oncol; 1996 Apr; 14(4):1093-7. PubMed ID: 8648362
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status.
Vijayakumar S; Weichselbaum R; Vaida F; Dale W; Hellman S
Cancer J Sci Am; 1996; 2(4):225-33. PubMed ID: 9166537
[TBL] [Abstract][Full Text] [Related]
24. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer.
Asbell SO; Vijayakumar S
Prostate; 1997 Apr; 31(1):42-6. PubMed ID: 9108885
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific antigen levels are higher in African-American than in white patients in a multicenter registration study: results of RTOG 94-12.
Vijayakumar S; Winter K; Sause W; Gallagher MJ; Michalski J; Roach M; Porter A; Bondy M
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):17-25. PubMed ID: 9422553
[TBL] [Abstract][Full Text] [Related]
26. PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation.
Hanks GE; Perez CA; Kozar M; Asbell SO; Pilepich MV; Pajak TF
Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):289-92. PubMed ID: 7523341
[TBL] [Abstract][Full Text] [Related]
27. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era.
Jani AB; Vaida F; Hanks G; Asbell S; Sartor O; Moul JW; Roach M; Brachman D; Kalokhe U; Muller-Runkel R; Ray P; Ignacio L; Awan A; Weichselbaum RR; Vijayakumar S
Int J Cancer; 2001 Dec; 96(6):363-71. PubMed ID: 11745507
[TBL] [Abstract][Full Text] [Related]
28. Characteristics and outcome of prostate cancer with PSA <4 ng/ml at diagnosis: a population-based study.
Bonet M; Merglen A; Fioretta G; Rapiti E; Neyroud-Caspar I; Zanetti R; Miralbell R; Bouchardy C
Clin Transl Oncol; 2009 May; 11(5):312-7. PubMed ID: 19451064
[TBL] [Abstract][Full Text] [Related]
29. Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries.
; Adamo MP; Boten JA; Coyle LM; Cronin KA; Lam CJ; Negoita S; Penberthy L; Stevens JL; Ward KC
Cancer; 2017 Feb; 123(4):697-703. PubMed ID: 27783399
[TBL] [Abstract][Full Text] [Related]
30. Race and the Will Rogers phenomenon in prostate cancer.
Vijayakumar S; Vaida F; Weichselbaum R; Hellman S
Cancer J Sci Am; 1998; 4(1):27-34. PubMed ID: 9467043
[TBL] [Abstract][Full Text] [Related]
31. The use of prostate-specific antigen kinetics to stratify risk in prostate cancer.
Presti J
Curr Urol Rep; 2008 May; 9(3):226-30. PubMed ID: 18765117
[TBL] [Abstract][Full Text] [Related]
32. Bayesian piecewise mixture model for racial disparity in prostate cancer progression.
Zhao L; Banerjee M
Comput Stat Data Anal; 2012 Feb; 56(2):362-369. PubMed ID: 25540470
[TBL] [Abstract][Full Text] [Related]
33. Author Correction: Pretreatment PSA levels affects the completion rate of Ra-223 treatment.
Utsumi N; Kurosaki H; Miura K; Kitoh H; Akakura K
Sci Rep; 2021 Aug; 11(1):16953. PubMed ID: 34400758
[No Abstract] [Full Text] [Related]
34. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer.
Rosser CJ; Kuban DA; Lee SJ; Levy LB; Pettaway C; Kamat AM; Chichakli R; Lee A; Cheung RM; Sanchez-Ortiz R; Pisters LL
J Natl Med Assoc; 2004 Jul; 96(7):939-44. PubMed ID: 15253325
[TBL] [Abstract][Full Text] [Related]
35. Differences between African American and Caucasian men participating in a community-based prostate cancer screening program.
Barber KR; Shaw R; Folts M; Taylor DK; Ryan A; Hughes M; Scott V; Abbott RR
J Community Health; 1998 Dec; 23(6):441-51. PubMed ID: 9824793
[TBL] [Abstract][Full Text] [Related]
36. Pretreatment prostate-specific antigen values in patients with prostate cancer: 1989 patterns of care study process survey.
Teshima T; Hanlon AM; Hanks GE
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):809-14. PubMed ID: 7591887
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
38. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer.
Kuban DA; el-Mahdi AM; Schellhammer PF
Int J Radiat Oncol Biol Phys; 1995 May; 32(2):307-16. PubMed ID: 7538499
[TBL] [Abstract][Full Text] [Related]
40. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
Zagars GK; Pollack A
Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
